BridgeMD
PREDICTION OF COMPLICATIONS IN PATIENTS UNDERGOING SURGICAL TREATMENT OF HEPATIC TUMORS
EU CTIS ID: 2025-524477-17-00
What this study is testing
1. To evaluate the correlation between Technetium-99m galactosyl human serum albumin combined with single-photon emission computed tomography fused with computed tomography (Tc-99m GSA SPECT/CT) and established liver function assessments, including indocyanine green (ICG) clearance test, Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, and ultrasound elastography. 2. To compare the discriminative ability of Tc-99m GSA SPECT/CT with existing liver function tests in predicting postoperative complications.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years
- Confirmed or suspected diagnosis of hepatic tumor
- Planned local treatment following a multidisciplinary team conference conducted at the Copenhagen University Hospital, Rigshospitalet
You likely can't join if
- Patients aged with a history of hypersensitivity to Technetium-99m or albumin
- Pregnant or breastfeeding individuals
- Participants unable to make autonomous care decisions
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.